In addition, a small molecule inhibitor of BRD4 that suppresses c-Myc transcription shows therapeutic effects against MM in vitro and in vivo, and the small molecule inhibitor 10058-F4a, that specifically inhibits c-Myc-Max heterodimerization, prevents the transactivation of c-Myc, induces cell death in human myeloma cell lines and primary cells of myeloma patients [18, 19]. This evidence concerns the gene BRD4 and plasma cell myeloma.